AbbVie agreed to pay up to $1.1 billion to gain ex‑China rights to Zelgen’s trispecific T‑cell engager alveltamig (ZG‑006), including a $100 million up‑front fee and more than $1 billion in contingent milestones plus tiered royalties, according to BioCentury. Zelgen retains China rights. Alveltamig targets DLL3, a rediscovered antigen in small‑cell lung cancer and other DLL3‑expressing malignancies; the asset represents a strategic bet by AbbVie on multispecific T‑cell engagers and next‑generation immunotherapies. Deal terms and the drug’s clinical profile suggest AbbVie expects a commercial opportunity outside China and is buying an advanced oncology asset to accelerate its T‑cell engager footprint.